Status:
COMPLETED
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Lead Sponsor:
Eisai Inc.
Conditions:
Myelodysplastic Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness and safety of two different dose schedules of DACOGEN® (decitabine) for Injection in patients with Myelodysplastic Syndromes (MDS).
Detailed Description
This is a randomized open-label Phase 2 efficacy and safety study of two (2) subcutaneous (SQ) dosing schedules of decitabine in subjects with Low or Intermediate 1 Risk MDS. This study will be conduc...
Eligibility Criteria
Inclusion
- Each patient must meet the following criteria to be enrolled in this study:
- Male or female patients age 18 years and older.
- Patients must sign an institutional review board (IRB)-approved informed consent form, and understand the investigational nature of this study and its potential hazards prior to initiation of any study-specific procedures or treatment.
- Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Adequate renal and hepatic function (creatinine \< 2 times upper limit of normal, total bilirubin of \< 2 times upper limit of normal, and AST and ALT ≤ 2 times upper limit of normal) unless proven to be related to disease infiltration.
- Female patients need a negative serum or urine pregnancy test within 7 days prior to study drug administration (applies only if patient is of childbearing potential. Non-childbearing is defined as ≥ 1 year postmenopausal or surgically sterilized).
- Women of childbearing potential and men must use contraception. Men and women must continue birth control for the duration of the study.
- Patients with Low or Intermediate-1 Risk MDS by the International Prognostic Scoring System (IPSS) classification.
Exclusion
- Patients who meet any of the following criteria will be excluded from the study:
- Women who are pregnant or nursing.
- Those who have received prior therapy with decitabine.
- Prior therapy with azacitidine (Vidaza®).
- Those who received growth factor support or lenalidomide in the 30 days prior to the first dose of decitabine.
- Those who have received an investigational agent 30 days prior to the first dose of decitabine.
- Patients with active, uncontrolled, systemic infection considered opportunistic, life threatening or clinically significant; or any severe, concurrent disease, which, in the judgment of the Investigator and after discussion with the Sponsor and Primary Investigator, would make the patient inappropriate for study entry.
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00619099
Start Date
May 1 2008
Last Update
October 24 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Gabrail Cancer Center
Canton, Ohio, United States, 44718
2
Landmark Medical Center
Woonsocket, Rhode Island, United States, 02895
3
Sarah Cannon Research
Nashville, Tennessee, United States, 37203
4
M. D. Anderson
Houston, Texas, United States, 77030